GI Innovation, Inc. (KOSDAQ:358570)
South Korea · Delayed Price · Currency is KRW 20,100
-800 (-3.83%)
Dec 10, 2025, 3:30 PM KST
GI Innovation Revenue
GI Innovation had revenue of 338.09M KRW in the twelve months ending September 30, 2025, down -92.89% year-over-year. In the year 2024, GI Innovation had annual revenue of 24.28M, down -99.54%.
Revenue (ttm)
338.09M
Revenue Growth
-92.89%
P/S Ratio
3,785.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.28T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.28M | -5.29B | -99.54% |
| Dec 31, 2023 | 5.32B | 1.82B | 51.97% |
| Dec 31, 2022 | 3.50B | -2.10B | -37.50% |
| Dec 31, 2021 | 5.60B | -5.42B | -49.17% |
| Dec 31, 2020 | 11.02B | 7.50B | 213.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |